Loading...
 

Volume 34, Issue 4, December 2023



Sign in to download the Issue in PDF format.

Mediterr J Rheumatol 2023;34(1):97-100
Large Vessel Vasculitis After the Administration of Oxford-AstraZeneca COVID-19 Vaccine
Authors Information

1Department of Pathophysiology, School of Medicine, National and Kapodistrian University of Athens, and Institute for Autoimmune Systemic and Neurologic Diseases, Athens, Greece

2Haematology Department, Athens Medical Centre, Athens, Greece

O Katsouli, VG Lainis, GG Kapellos, PG Vlachoyiannopoulos

References
  1. Hellmich B, Agueda A, Monti S, Buttgereit F, de Boysson H, Brouwer E, et al. 2018 Update of the EULAR recommendations for the management of large vessel vasculitis. Ann Rheum Dis 2020 Jan;79(1):19-30.
  2. Jaikaran O, Nicoara M, Hingorani A. Noninfectious aortitis: A case report. Vascular 2020 Oct;28(5):609-11.
  3. Shchetynska-Marinova T, Amendt K, Sadick M, Keese M, Sigl M. Aortitis - An Interdisciplinary Challenge. In Vivo 2021 Jan-Feb;35(1):41-52.
  4. Bonetto C, Trotta F, Felicetti P, Alarcón GS, Santuccio C, Bachtiar NS, et al. Brighton Collaboration Vasculitis Working Group. Vasculitis as an adverse event following immunization - Systematic literature review. Vaccine 2016 Dec 12;34(51):6641-51.
  5. Oda R, Inagaki T, Ishikane M, Hotta M, Shimomura A, Sato M, et al. Case of adult large vessel vasculitis after SARS-CoV-2 infection. Ann Rheum Dis 2023 Jan;82(1):e25.
  6. Kim Y, Kang J, Lee SG, Kim GT. COVID-19 vaccination-related small vessel vasculitis with multiorgan involvement. Z Rheumatol 2022;81:509-12.
  7. Corrà A, Verdelli A, Mariotti EB, Ruffo di Calabria V, Quintarelli L, Aimo C, et al. Cutaneous vasculitis: Lessons from COVID-19 and COVID-19 vaccination. Front Med. 9:1013846.
  8. Tesch F, Ehm F, Vivirito A, Wende D, Batram M, Loser F, et al. Incident autoimmune diseases in association with a SARS-CoV-2 infection: A matched cohort study. https://doi.org/10.1101/2023.01.25.23285014
  9. Abdelmaksoud A, Wollina U, Temiz SA, Hasan A. SARS-CoV-2 vaccination-induced cutaneous vasculitis: Report of two new cases and literature review. Dermatol Ther 2022 Jun;35(6):e15458.
  10. Gilio M, De Stefano G. Large vessel vasculitis following the Pfizer BioNTech COVID 19 vaccine. Intern Emerg Med 2022; 17(4): 1239-41.
  11. Vasculitis and administration of COVID-19 vaccines. Netherlands Pharmacovigilance Centre Lareb. https://www.lareb.nl/media/x30nhooz/signal_2021_vasculitis-and-administration-of-covid-19-vaccines_gws.pdf
  12. COVID-19 vaccine AstraZeneca analysis print. https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1115342/COVID-19_Vaccine_AstraZeneca_analysis_print_-_26OCT22.pdf
  13. Teijaro JR, Farber DL. COVID-19 vaccines: modes of immune activation and future challenges. Nat Rev Immunol 2021; 21(4):195-7.
  14. Harky A, Fok M, Balmforth D, Bashir M. Pathogenesis of large vessel vasculitis: Implications for disease classification and future therapies. Vasc Med 2019 Feb;24(1):79-88.
  15. Dotan A, Muller S, Kanduc D, David P, Halpert G, Shoenfeld Y. The SARS-CoV-2 as an instrumental trigger of autoimmunity. Autoimmun Rev 2021 Apr;20(4):102792.
  16. Liozon E, Parreau S, Filloux M, Dumonteil S, Gondran G, Bezanahary H, et al. Giant cell arteritis or polymyalgia rheumatica after influenza vaccination: A study of 12 patients and a literature review. Autoimmun Rev 2021 Feb;20(2):102732.
  17. Quartuccio L, Maset M, De Maglio G, Pontarini E, Fabris M, Mansutti E, et al. Role of oral cyclophosphamide in the treatment of giant cell arteritis. Rheumatology 2012 Sep;51(9):1677-86.
  18. de Boysson H, Boutemy J, Creveuil C, Ollivier Y, Letellier P, Pagnoux C,  et al. Is there a place for cyclophosphamide in the treatment of giant-cell arteritis? A case series and systematic review. Semin Arthritis Rheum 2013 Aug;43(1):105-12.
  19. Henes JC, Mueller M, Pfannenberg C, Kanz L, Kötter I. Cyclophosphamide for large vessel vasculitis: assessment of response by PET/CT. Clin Exp Rheumatol 2011 Jan-Feb;29(1 Suppl 64):S43-8.